WANBURYWanbury Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on WANBURY — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 116.6% YoY
- • ROE: 45.8%
- • ROCE: 25.1%
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 27
- • Sector momentum: sector +6.2% (1m)
Bull case
- • Profit growth: 116.6% YoY
- • ROE: 45.8%
- • ROCE: 25.1%
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: -19.2% YoY
- • Debt/Equity: 1.55
- • RSI: 35
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Revenue growth: -19.2% YoY
- • Debt/Equity: 1.55
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹11.35). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.